News Listing

Get access to local coverage insights with the new payer coverage lookup tool for select RA patients for a Genentech product.

Attending the NORM Annual Conference at the Hyatt Regency in New Orleans, LA?  Following the NORM Welcome Reception, you’re invited to join us at Rheum for conversations, a Cardinal Health reception for an opportunity to network and best practice share with peers.  

Bristol Myers Squibb announced on March 6, 2026, that the U.S. Food and Drug Administration (FDA) approved SOTYKTU® (deucravacitinib), a selective tyrosine kinase 2 (TYK2) inhibitor.1,2
SOTYKTU® (deucravacitinib) has been approved for the treatment of adults with...

The momentum surrounding Pharmacy Benefit Manager (PBM) oversight continues to grow. With bipartisan support, attention is intensifying on how PBM practices impact drug affordability, patient access, and the broader healthcare system. Federal agencies and state regulators along with Congress are all playing key roles in shaping the policy conversation that will define the future of PBM regulation ...

Exciting things are happening in 2026—introducing BIMZELX Navigate® program enhancements! As of January 1, 2026, the BIMZELX Navigate program has been upgraded with new features and streamlined processes to better support both your patients and practice.

Support is available to help your patients with lupus nephritis start and stay on a prescribed Genentech medication. Genentech is committed to helping patients access…

NORM proudly supports lupus patients and the Lupus Foundation, and we honor the rheumatologists who care for them every day. In May, communities across the country come together to recognize Lupus Awareness Month — a time dedicated to increasing understanding, supporting those living with lupus, and advocating for better care and research. On May 10, the global community also recognizes World ...

Permanent HCPCS Level II Coding for Organon’s biosimilars to PROLIA (denosumab) and XGEVA (denosumab) is now effective. Q-code: Q5162

We want to make you aware of a new CMS requirement that requires your urgent attention to avoid potential disruption to eligibility checks and benefit investigations performed on your behalf by Amgen.

The national conversation around Pharmacy Benefit Managers (PBMs) often centers on drug pricing. In rheumatology practices, however, the impact goes far beyond cost. It affects operations, financial stability, physician morale, and—most importantly—patient access to care.